We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Omega-3 Fatty Acids Block Macrophage Inflammatory Action

By LabMedica International staff writers
Posted on 13 Sep 2010
A possible dietary approach for ameliorating the symptoms of diabetes is based on omega-3 fatty acids, which recently have been shown to activate a critical inflammation suppressing signaling pathway.

Investigators at the University of California, San Diego (USA) worked with cells growing in culture and with a line of genetically engineered mice to study the relationship between omega-3 fatty acids and the G-protein receptor, GPR120. More...
GPR120, which is limited to fat tissue and macrophages, is a member of a large protein family many of whose members are drug targets.

The investigators reported in the September 3, 2010, issue of the journal Cell that the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) bind to and activate GPR120. Activated GPR120 triggers a molecular pathway that blocks the macrophages' inflammatory role.

They fed obese mice and mice genetically engineered to lack the gene for GPR120 (GPR120 knockout mice) a high fat diet with or without omega-3 fatty acid supplementation. The omega-3 treatment inhibited inflammation and enhanced systemic insulin sensitivity in the obese mice, but was without effect in GPR120 knockout mice.

"It is just an incredibly potent effect,” said senior author Dr. Jerrol Olefsky, professor of medicine at the University of California, San Diego. "The omega-3 fatty acids switch on the receptor, killing the inflammatory response. The receptor evolved to respond to a natural product – omega-3 fatty acids – so that the inflammatory process can be controlled. Our work shows how fish oils safely do this, and suggests a possible way to treating the serious problems of inflammation in obesity and in conditions like diabetes, cancer, and cardiovascular disease through simple dietary supplementation.”

Related Links:
University of California, San Diego


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.